The content on this site is intended for healthcare professionals only
A new treatment paradigm in multiple myeloma
Advances with bendamustine in multiple myeloma from EHA 2012
Advances in multiple myeloma from EHA 2012
Advances in multiple myeloma from EHA 2012; bortezomib and beyond
Dasatinib vs. imatinib first-line in CML; new study data
The evolving landscape in CML management
AZA in MDS, and managing the older MDS patient
Lenalidomide in low-risk MDS del(5q)
EHA 2012 advances in lymphoma; lenalidamide and beyond
Identifying drug sensitivity and resistance in acute myeloid leukaemia
Addressing the problem of adherence to treatment
Patient and doctor communication and quality of life guidelines
